EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Reduced Serological Response to COVID-19 Booster Vaccine is Associated with Reduced B Cell Memory in Patients With Inflammatory Bowel Disease; VARIATION [VAriability in Response in IBD AgainsT SARS-COV-2 ImmunisatiON]

Jayne Doherty iD, Neil O'Morain, Roisin Stack, Miriam Tosetto, Rosanna Inzitiari, Sophie O'Reilly, Lili Gu, Juliette Sheridan, Garret Cullen, Edel Mc Dermott, Maire Buckley, Gareth Horgan und 10 weitere

Journal of Crohn's and Colitis · 2023

DOI: 10.1093/ecco-jcc/jjad065 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Crohn's and Colitis, 2023. Verfasst von Jayne Doherty und 21 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, COVID-19, SARS-CoV-2, COVID-19 Vaccines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: University College Dublin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Patients with inflammatory bowel disease [IBD] have an attenuated response to initial COVID-19 vaccination. We sought to characterize the impact of IBD and its treatment on responses after the third vaccine against SARS-CoV-2.

Methods

This was a prospective multicentre observational study of patients with IBD [n = 202] and healthy controls [HC, n = 92]. Serological response to vaccination was assessed by quantification of anti-spike protein [SP] immunoglobulin [Ig]G levels [anti-SPIgG] and in vitro neutralization of binding to angiotensin-converting enzyme 2 [ACE2]. Peripheral blood B-cell phenotype populations were assessed by flow cytometry. SARS-CoV-2 antigen-specific B-cell responses were assessed in ex vivo culture.

Results

Median anti-SP IgG post-third vaccination in our IBD cohort was significantly lower than HCs [7862 vs 19 622 AU/mL, p < 0.001] as was ACE2 binding inhibition [p < 0.001]. IBD patients previously infected with COVID-19 [30%] had similar quantitative antibody response as HCs previously infected with COVID-19 [p = 0.12]. Lowest anti-SP IgG titres and neutralization were seen in IBD patients on anti-tumour necrosis factor [anti-TNF] agents, without prior COVID-19 infection, but all IBD patients show an attenuated vaccine response compared to HCs. Patients with IBD have reduced memory B-cell populations and attenuated B-cell responses to SARS-CoV-2 antigens if not previously infected with COVID-19 [p = 0.01]. Higher anti-TNF drug levels and zinc levels <65 ng/ml were associated with significantly lower serological responses.

Conclusions

Patients with IBD have an attenuated response to three doses of SARS-CoV-2 vaccine. Physicians should consider patients with higher anti-TNF drug levels and/or zinc deficiency as potentially at higher risk of attenuated response to vaccination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesCOVID-19SARS-CoV-2COVID-19 VaccinesImmunization, SecondaryMemory B CellsB-LymphocytesHumansFemaleMaleAdultMiddle AgedProspective StudiesAntibodies, ViralImmunoglobulin GSpike Glycoprotein, CoronavirusImmunologic Memory

Stichwörter der Autor:innen

COVID-19 vaccinationInflammatory bowel diseaseimmune responsememory B-cell response

Substanzen

COVID-19 VaccinesAntibodies, ViralImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland.
  • School of Medicine, University College Dublin, Dublin, Ireland.
  • INITIative IBD Research Network (www.initiativeibd.ie).
  • Centre for Experimental Pathogen Host Research, School of Medicine, University College Dublin, Ireland.
  • St Michaels Hospital, Dun Laoghaire, Co Dublin, Ireland.
  • St Columcille's Hospital, Loughlinstown, Co Dublin, Ireland.

ORCID-Profile: Jayne Doherty

Förderung

  • University College Dublin

Zitieren

APA

Doherty, J., O'Morain, N., Stack, R., Tosetto, M., Inzitiari, R., O'Reilly, S., Gu, L., Sheridan, J., Cullen, G., Mc Dermott, E., Buckley, M., Horgan, G., Mulcahy, H., Walshe, M., Ryan, E. J., Gautier, V., Prostko, J., Frias, E., Daghfal, D., …, & Doherty, G. A. (2023). Reduced Serological Response to COVID-19 Booster Vaccine is Associated with Reduced B Cell Memory in Patients With Inflammatory Bowel Disease; VARIATION [VAriability in Response in IBD AgainsT SARS-COV-2 ImmunisatiON]. Journal of Crohn's and Colitis. https://doi.org/10.1093/ecco-jcc/jjad065

Vancouver

Doherty J, O'Morain N, Stack R, Tosetto M, Inzitiari R, O'Reilly S, et al. Reduced Serological Response to COVID-19 Booster Vaccine is Associated with Reduced B Cell Memory in Patients With Inflammatory Bowel Disease; VARIATION [VAriability in Response in IBD AgainsT SARS-COV-2 ImmunisatiON]. Journal of Crohn's and Colitis. 2023. doi:10.1093/ecco-jcc/jjad065

BibTeX
@article{Doherty2023,
  author = {Doherty, Jayne and O'Morain, Neil and Stack, Roisin and Tosetto, Miriam and Inzitiari, Rosanna and O'Reilly, Sophie and Gu, Lili and Sheridan, Juliette and Cullen, Garret and Mc Dermott, Edel and Buckley, Maire and Horgan, Gareth and Mulcahy, Hugh and Walshe, Margaret and Ryan, Elizabeth J and Gautier, Virginie and Prostko, John and Frias, Edwin and Daghfal, David and Doran, Peter and O'Morain, Colm and Doherty, Glen A},
  title = {Reduced Serological Response to COVID-19 Booster Vaccine is Associated with Reduced B Cell Memory in Patients With Inflammatory Bowel Disease; VARIATION [VAriability in Response in IBD AgainsT SARS-COV-2 ImmunisatiON]},
  journal = {Journal of Crohn's and Colitis},
  year = {2023},
  doi = {10.1093/ecco-jcc/jjad065}
}
Kostenlos starten →